Chemosensitizer Effects of Coencapsulation of Curcumin and Cabazitaxel in Nanostructured Lipid Carriers in Glioblastoma Cells
ACS Omega · 24.03.2026 · 11 (11) · 17223-17234
DOI: 10.1021/acsomega.5c08442 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 11.03.2026. Verfasst von Franciely Rufino de Almeida Lima und 2 weiteren Autor:innen. Beteiligte Einrichtung: GNanoBio, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitair Medisch Centrum Groningen, Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Gliomas are the most common primary tumors of the central nervous system and are associated with poor prognosis. Current therapy with Temozolomide shows limited efficacy, highlighting the need for new treatment options. Cabazitaxel (CBZ), a chemotherapeutic agent approved for prostate cancer, has shown efficacy in preclinical glioblastoma models. However, there is a need for strategies to reduce toxicity and enhance delivery. Curcumin (CUR), known for its antitumor, anti-inflammatory, and antioxidant properties, has been investigated as a potential chemosensitizer. Here, we developed and characterized a nanostructured lipid carrier (NLC) for codelivery of CBZ and CUR, evaluating its cytotoxic effect on U87MG GBM cells. The NLCs were optimized using a Box–Behnken design and exhibited a size below 150 nm, low polydispersity, and stability. The NLC–CUR/CBZ showed spherical morphology and low crystallinity that contributed to high encapsulation efficiency of both compounds (>98%). Furthermore, this system exhibited high cellular internalization and cytotoxic activity, reducing the IC 50 by 2.418 times compared to free CBZ, and induced predominantly apoptotic cell death. The results highlight the potential of CUR and CBZ coencapsulation in NLCs for GBM treatment, providing a basis for future clinical investigations.
Autor:innen und Institutionen
- GNanoBio, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo 14040-903, Brazil.
- Department of Biomaterials and Biomedical Technology, The Personalized Medicinee Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The N…
ORCID-Profile: Hélder A Santos, Priscyla D Marcato
Förderung
- Universitair Medisch Centrum Groningen
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo
Zitieren
APA
de Almeida Lima, F. R., Santos, H. A., & Marcato, P. D. (2026). Chemosensitizer Effects of Coencapsulation of Curcumin and Cabazitaxel in Nanostructured Lipid Carriers in Glioblastoma Cells. ACS Omega, 11(11), 17223-17234. https://doi.org/10.1021/acsomega.5c08442
Vancouver
de Almeida Lima FR, Santos HA, Marcato PD. Chemosensitizer Effects of Coencapsulation of Curcumin and Cabazitaxel in Nanostructured Lipid Carriers in Glioblastoma Cells. ACS Omega. 2026;11(11):17223-17234. doi:10.1021/acsomega.5c08442
BibTeX
@article{deAlmeidaLima2026,
author = {de Almeida Lima, Franciely Rufino and Santos, Hélder A and Marcato, Priscyla D},
title = {Chemosensitizer Effects of Coencapsulation of Curcumin and Cabazitaxel in Nanostructured Lipid Carriers in Glioblastoma Cells},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {11},
pages = {17223--17234},
doi = {10.1021/acsomega.5c08442}
}
EUVIMED